Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Complexin-2 CRISPR/Cas9 KO Plasmid (h): sc-406799
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Complexin-2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Complexin-2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Complexin-2 CRISPR/Cas9 KO Plasmid (h) | sc-406799 | 20 µg | $397.00 |
Overview
CPLX2 encodes complexin-2, a presynaptic cytosolic protein that binds assembled SNARE complexes to regulate synaptic vesicle priming and calcium-triggered exocytosis. By modulating vesicle fusion probability and synchronous neurotransmitter release, complexin-2 contributes to activity-dependent neurotransmission and short-term synaptic plasticity. CPLX2-linked dysfunction has been investigated in the context of altered excitatory/inhibitory balance and circuit-level phenotypes relevant to neuropsychiatric and neurodevelopmental disorders, as well as synaptic changes associated with neurodegeneration. These features make CPLX2 a useful node for dissecting SNARE-mediated membrane fusion, Ca2+-dependent signaling, and presynaptic vesicle cycle control in human cellular models.
Complexin-2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CPLX2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CPLX2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CPLX2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Complexin-2 protein expression.
This CRISPR knockout system enables efficient generation of CPLX2-deficient cell models for investigation of Complexin-2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CPLX2 exon(s) critical for Complexin-2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CPLX2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Complexin-2 CRISPR/Cas9 KO Plasmid (h) and Complexin-2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CPLX2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Complexin-2 HDR Plasmid (h) and Complexin-2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CPLX2 homology arms to support homology-directed repair at defined CPLX2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.